An Edinburgh-based biotech company has sealed a £2 million funding injection to advance the treatment of haemophilia.
ProFactor Pharma (PFP), which is based just outside the capital at the Roslin Innovation Centre, has secured the money in a funding round led by the investment syndicate Kelvin Capital and supported by Ingenza and the Scottish Investment Bank, the investment arm of Scottish Enterprise.
The funding will be used for process optimisation and toxicology studies to enter clinical trials after 12 months as the firm continues to develop a low cost treatment for haemophilia A.
Read more HERE.
